Instead, this study clearly demonstrates that DCE-MRI with an albumin-binding contrast agent is able to capture early changes in tumor vasculature after both antiangiogenic treatment and immune checkpoint blockade, while revealing different response patterns between tumors with varying grade of malignancy. The gene discussed is ALB; the disease is neoplasm.